• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Uncategorized Page 8

Uncategorized

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

William Leonard Pickard interviews Bryan Hubbard about the new policy frontier of Ibogaine

Psychedelic legend “the Acid King” William Leonard Pickard Announced as Keynote Speaker at the 2025 North Florida Entheogenic Conference

Hello world!

atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference

atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase...

atai Life Sciences Announces Successful Outcome of Phase 2a Biomarker Trial...

atai Life Sciences Has Been Selected for Addition to the NASDAQ...

atai Life Sciences launches TryptageniX to further expand atai’s robust intellectual...

atai Life Sciences Increases its Ownership Position in COMPASS Pathways

atai Life Sciences Reports Third Quarter 2021 Financial Results and Corporate...

atai Life Sciences to Host Conference Call and Webcast to Discuss...

atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for...

atai Life Sciences to Participate in Upcoming January Investor Conference

Psygen Industries Ltd letter to Health Canada re: SAP

The Psilocybin Supply Chain: An Evidence-Based Review

1...789...13Page 8 of 13

EDITOR PICKS

Pα+ Psychedelic Bulletin #207: Lykos Rebrands to Resilient; Pharma Pushes Back...

Matt Xavier -The Psychedelic DJ

AbbVie to Acquire Gilgamesh’s Bretisilocin for Up to $1.2B

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©